[Chronic Kidney Disease - Update 2018].

UNLABELLED: SGLT2-INHIBITION IN DIABETIC AND NON-DIABETIC KIDNEY DISEASE:  The CANVAS Program Collaborative Group study confirmed nephroprotective actions by canagliflocin comparable to empagliflozin as published in the EMPA-REG Outcome study. Treatment with Liraglutide (LEADER study) also suggests nephroprotection via albuminuria reduction a decreased eGFR decline in subgroups and depending on stages of diabetic nephropathy. KDIGO CKD-MBD GUIDELINE UPDATE 2017:  In July 2017, an update of the KDIGO (Kidney Disease: Improving Global Outcomes) 2009 guideline on diagnostic and treatment chronic kidney disease - mineral and bone disorders (CKD-MBD) was published. Changes focused on the judgement of bone mineral density measurements, therapy of hyperphosphatemia and secondary hyperparathyroidism in CKD patients not on dialysis and on advising caution concerning excess calcium exposition.

A NOVEL PARENTERAL CALCIMIMETIC: Two phase 3 studies on the use of a new parenteral calcimimetic drug (etelcalcitide) were published in 2017.